Phosphoric Acid Derivatives Group
These substances were identified for action under the Chemicals Management Plan (CMP). The screening assessment focuses on 3 of 6 substances referred to collectively as the Phosphoric Acid Derivatives Group.
|Substance group||CAS RN||Common name||DSL name||Public comments on the draft screening assessment||Final screening assessment||Conclusion on section 64 criteria||Follow-up activities|
|Phosphoric Acid Derivatives Group||25155-23-1||Trixylyl phosphate||Phenol, dimethyl-, phosphate (3:1)||HTML||HTML||Does not meet||Significant New Activity (SNAc) provisions|
|37310-83-1Table 1 Footnote a||Oleyl phosphate||9-Octadecen-1-ol, (Z)-, phosphate||None planned at this time|
|119345-01-6Table 1 Footnote aTable 1 Footnote b||N/A||Phosphorous trichloride, reaction products with 1,1-biphenyl and 2,4-bis(1,1-dimethylethyl)phenol|
While trixylyl phosphate is not considered to be harmful to human health at levels of exposure considered in the assessment, it is considered to have a health effect of concern due to its potential to cause effects on the reproductive system. Therefore, there may be a concern if exposures were to increase. The proposed follow-up activity for trixylyl phosphate is to apply the SNAc provisions of CEPA 1999.
|December 19, 2020||Publication in the Canada Gazette, Part I: Vol. 154, No. 51 of the SNAc notice of intent and start of a 60-day public comment period.|
|December 19, 2020||Publication of the final screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 154, No. 51.|
|July 13, 2019||
Publication and start of 60-day public comment period on the draft screening assessment. The related notice was published in the Canada Gazette, Part I: Vol. 153, No. 28.
Three other substances were identified as being a part of the Phosphoric Acid Derivatives Group at the outset of the third phase of the CMP. These substances were subsequently determined to be of low concern to both human health and the environment, through other approaches. Conclusions for CAS RNs 68604-99-9, 68952-35-2, 111174-61-9 are provided in the Final Screening Assessment for the Rapid Screening of Substances with Limited General Population Exposure.
Report a problem or mistake on this page
- Date modified: